--- source_url: https://hangovr180.com/science/dhm/adh-aldh-pathway.md canonical_url: https://hangovr180.com/science/dhm/adh-aldh-pathway generated_at: 2026-06-28T19:53:17Z build_id: ebfcfef page_type: science-leaf claim_ids: [SF-22, SF-21, SF-20] --- # HOW DHM WORKS: THE ADH/ALDH PATHWAY *Two enzymes do the actual work of clearing alcohol from your body. DHM helps them do it faster, and the published data is clearer than the supplement industry lets on.* These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. ## The Two Enzymes That Actually Matter When you drink, your liver does most of the cleanup work, and the pathway is short. Alcohol dehydrogenase (ADH) converts ethanol into acetaldehyde. Aldehyde dehydrogenase (ALDH) then converts that acetaldehyde into acetate, which your body breaks down into water and carbon dioxide and clears out[1]. Acetaldehyde is the problem molecule in this whole sequence. It is classified as a known carcinogen, it binds readily to proteins and DNA, and it is the chemical mostly responsible for flushing, nausea, and the morning-after damage people associate with drinking[1]. The longer it lingers, the more harm it does. So the speed of step two -- ALDH clearing acetaldehyde -- matters more than almost anything else in the pathway. ## Why the Pathway Bottlenecks ADH is fast at the start. ALDH is slower. That mismatch is the entire reason hangovers exist as a category of human suffering. The genetic variant that causes the so-called Asian flush is a useful natural experiment here: people who carry the ALDH2 variant convert ethanol to acetaldehyde at normal speed but cannot clear the acetaldehyde efficiently, and the symptoms scale almost exactly with how much of it accumulates[2]. There is a second bottleneck too, and it is NAD+. Both ADH and ALDH need NAD+ as a cofactor to do their jobs, and ethanol metabolism depletes NAD+ in the liver as it runs. When NAD+ drops, both enzymes slow down, which is why a third drink lingers longer than a first. ## What DHM Does to the Pathway > **Claim [SF-22]:** Triggers the liver to produce more of the aldehyde- and alcohol-metabolizing enzymes (ADH and ALDH) and boosts their efficiency in breaking down aldehydes and alcohols in foods as well as their by-products. † > > † These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. DHM does not replace ADH or ALDH. It induces them -- meaning the liver produces more of them -- and it helps restore the NAD+ that ethanol depletes during cleanup. In a 2020 mouse study, animals given DHM showed lower serum ethanol, lower serum acetaldehyde, restored hepatic NAD+, and induced expression of both ADH1 and ALDH2 compared to controls[3]. > **Claim [SF-21]:** Acts by promoting aldehyde and alcohol metabolism of foods. † > > † These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. But the enzyme story isn't the whole picture, and I want to be honest about that. A 2021 review titled "Does Dihydromyricetin Impact on Alcohol Metabolism?" looked at the mixed evidence and concluded that DHM's protective effect on the liver probably comes from a combination of mechanisms -- enhanced ethanol metabolism, reduced oxidative stress, NAD+ restoration, and lipid oxidation pathways -- rather than enzyme upregulation alone[4]. (this is one of those situations where the popular explanation is partially right but oversimplified.) ## What That Looks Like in a Person I'm not a biochemist. I am a guy who ran 150 self-experiments over six months because nothing on the market actually worked, and the ADH/ALDH model is the one that best explains what I kept seeing in my own data. Drinks felt like they cleared faster. The morning-after aldehyde fog, that specific cognitive slowness I now recognize as acetaldehyde load, showed up much less often. The 2012 paper by Shen and colleagues, which is the study that first put DHM on most researchers' radar, demonstrated that same kind of acetaldehyde reduction in animals at doses scaled to what we eventually landed on for the formula[5]. > **Claim [SF-20]:** Lowers liver enzyme (AST and ALT) levels that are already in the normal range. † > > † These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. DHM also reduces the markers of liver stress (AST and ALT) when those values sit in teh normal range, which is what you would expect if the enzyme system is doing its job more efficiently and the liver is taking less collateral damage during cleanup[3]. ## What This Page Is Not Claiming DHM is not a license to drink more. The pathway has limits, the liver has limits, and acetaldehyde damage scales with total exposure regardless of how fast you clear it. What DHM does is shift the curve so you metabolize the same amount of alcohol with less acetaldehyde lingering between step one and step two. That is the mechanism. That is what the published animal data supports. The dose math behind why we use 1,500mg of DHM specifically is covered on the [DHM dose-response page](/science/dhm/dose-response), and the GABA side of DHM (a separate mechanism that affects how alcohol feels rather than how it metabolizes) is covered in [DHM and GABA modulation](/science/dhm/gaba-modulation). ## Citations 1. NIAAA. [Alcohol Metabolism](https://www.niaaa.nih.gov/publications/alcohol-metabolism). niaaa.nih.gov. 2. Edenberg HJ. [The Genetics of Alcohol Metabolism -- Role of Alcohol Dehydrogenase and Aldehyde Dehydrogenase Variants](https://pmc.ncbi.nlm.nih.gov/articles/PMC3860432/). PMC3860432. 3. Silva J, et al. [Dihydromyricetin Protects the Liver via Changes in Lipid Metabolism and Enhanced Ethanol Metabolism](https://pmc.ncbi.nlm.nih.gov/articles/PMC7211127/). PMC7211127. 4. Carneiro A, et al. [Does Dihydromyricetin Impact on Alcohol Metabolism?](https://pmc.ncbi.nlm.nih.gov/articles/PMC8603706/) PMC8603706. 5. Shen Y, et al. [Dihydromyricetin As a Novel Anti-Alcohol Intoxication Medication](https://pmc.ncbi.nlm.nih.gov/articles/PMC3292407/). PMC3292407. ## Read Next - [DHM -- The Hub](/science/dhm) - [DHM Dose-Response -- Why 1,500mg Matters](/science/dhm/dose-response) - [DHM and GABA Modulation Explained](/science/dhm/gaba-modulation) - [The Formula](/science/formula) **Written by Mark Scott** - Co-Formulator, Hangovr180® | Co-Inventor, [US Application 18/698,010](https://patents.google.com/patent/US20250073201A1) Mark Scott conducted approximately 150 personal formulation tests over six months to develop the H180 ingredient combination. [Editorial standards](/editorial-standards) --- These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Hangovr180® is a dietary supplement. Individual results may vary. Consult your healthcare provider before use if you have any medical conditions or take medications. [US Application 18/698,010](https://patents.google.com/patent/US20250073201A1). Canonical: https://hangovr180.com/science/dhm/adh-aldh-pathway